Ix Biopharma
Ix Biopharma Ltd, commonly referred to as Ix Biopharma, is a pioneering biopharmaceutical company headquartered in Singapore, with significant operations across Asia and beyond. Founded in 2008, the company has established itself in the pharmaceutical industry, focusing on the development of innovative drug delivery systems and therapeutic solutions. Ix Biopharma is renowned for its proprietary WaferiX® technology, which enables the rapid absorption of active pharmaceutical ingredients through the oral mucosa. This unique approach sets the company apart in the market, offering patients improved efficacy and convenience. With a strong commitment to research and development, Ix Biopharma has achieved notable milestones, including partnerships with leading pharmaceutical firms and a growing portfolio of products aimed at addressing unmet medical needs. As a result, the company has positioned itself as a key player in the biopharmaceutical landscape, driving advancements in drug delivery and patient care.
DitchCarbon Score
How does Ix Biopharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Instruments industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Ix Biopharma's score of 17 is lower than 96% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Ix Biopharma's reported carbon emissions
In 2024, Ix Biopharma reported carbon emissions of approximately 949,000 kg CO2e, primarily from Scope 2 emissions, which pertain to indirect emissions from purchased electricity. This figure represents a slight increase from 2023, where emissions were about 937,000 kg CO2e. In 2022, the company achieved a notable reduction, with emissions recorded at approximately 714,000 kg CO2e, indicating a significant decrease from the previous year. Despite these fluctuations, Ix Biopharma has not set specific reduction targets or commitments under frameworks such as the Science Based Targets initiative (SBTi) or the Carbon Disclosure Project (CDP). The absence of formal climate pledges suggests that while the company is actively monitoring its emissions, it has yet to establish a comprehensive strategy for long-term carbon reduction. Overall, Ix Biopharma's emissions data highlights the importance of ongoing efforts to manage and reduce carbon footprints within the biopharmaceutical industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Scope 1 | - | - | - | - |
| Scope 2 | 997,000 | 000,000 | 000,000 | 000,000 |
| Scope 3 | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Ix Biopharma is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
